Atezolizumab

Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC): After prior chemotherapy, or Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression. Tecentriq is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer NSCLC after prior chemotherapy.

Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells suppresses cytotoxic T-cell activity through the inhibition of T-cell proliferation and cytokine production. PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells, and can contribute to the inhibition of the antitumor immune response in the microenvironment. Atezolizumab is an Fc-engineered humanized immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors, releasing PD-L1 / PD-1 pathway-mediated inhibition of the immune response, including reactivating the antitumor immune response. Atezolizumab leaves the PD-L2/PD-1 interaction intact. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth

General : Atezolizumab must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Atezolizumab must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Atezolizumab is either: 1200 mg administered by IV infusion every 3 weeks or 1680 mg administered by IV infusion every 4 weeks. 1L cisplatin-ineligible mUC : Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test